AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 281 min read$TXG

Saxonov Serge sold $668K of TXG

Saxonov Serge (Chief Executive Officer) sold 10,486 shares of 10x Genomics, Inc. (TXG) at an average of $63.69 ($63.02–$64.75, $0.67M total) across 3 trades on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Saxonov Serge
Published Aug 28, 2026, 11:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TXG
Bearish
medium confidence
Mentioned
$TXG
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TXGBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new data for traders.

02

Market read

First‑report insider sale adds modest bearish pressure but is unlikely to move the stock significantly.

03

What to watch

Potential upcoming product milestones or financing events not disclosed.

Relevance 4/10Novelty 4/10Timing: post‑market 2026-08-26

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$TXGBearishMedium confidence
Context

CEO Serge Saxonov sold 10,486 shares for $667,900 via a 10b5-1 plan on 2026-08-26.

Expected impact

Potential modest dip in TXG price over the next few days.

Evidence & confidence

The sale size is modest relative to total holdings and market cap, but it is a direct insider disposition.

Market effects

Sector

Minimal impact on biotech/genomics sector.

Regional

No regional effect.

Global

Limited to investors tracking 10b5‑1 insider activity.

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

  • Company
    10x Genomics, Inc.

    US‑listed biotech firm (ticker TXG).

  • Individual
    Saxonov Serge

    CEO of 10x Genomics, reporting insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TXG insider trading history →

Related articles

SEP 3
$TXGMed

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.

tradingview.com3 min
AUG 18
$TXGMed

10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform

10x Genomics (NASDAQ:TXG) reported Q2 revenue of $151m, including a $1.6m Takara settlement; excluding it, revenue was $149.4m, up 3% YoY. Atera booked orders already exceed planned 2026 shipments (~40 units). Cash rose to $552m and gross margin to 74%. Full-year revenue guidance raised to $610m-$630m; instrument revenue fell 47% YoY.

yahoo.com3 min
AUG 14
$TXGMedAI 9/10

10x Genomics (TXG) Q2 2026 Earnings Call Transcript

10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.

fool.com10 min
AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min